Elevation Oncology (ELEV)
(Delayed Data from NSDQ)
$2.93 USD
+0.04 (1.38%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $2.94 +0.01 (0.34%) 6:16 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELEV 2.93 +0.04(1.38%)
Will ELEV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ELEV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELEV
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?
ELEV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ELEV
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Elevation Oncology (ELEV) Receives a Buy from TD Cowen
Elevation Oncology’s EO-3021: A Promising Candidate in the Treatment Landscape for GEJ and GC
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
Elevation Oncology to evaluate combination in gastroesophageal junction cancer